NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR

NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR

Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for...

Telix Adds Lead-212 Isotope Production Capability

Telix Adds Lead-212 Isotope Production Capability

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the...

Huawei's Smart String & Grid Forming ESS Triumphs in Extreme Ignition Test

Huawei's Smart String & Grid Forming ESS Triumphs in Extreme Ignition Test

SHENZHEN, China, March 6, 2025 /PRNewswire/ -- Huawei Digital Power's Smart String & Grid Forming Energy Storage System (ESS) has successfully passed the extreme ignition test, witnessed by customers and DNV, a globally recognized independent...

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 25, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM...

menu
menu